Depot bromperidol decanoate for schizophrenia.

Area of Science:

• Psychiatry and Pharmacology
• Clinical Neuroscience
• Evidence-Based Medicine

Background:

• Antipsychotic medications are primary treatments for schizophrenia.
• Long-acting injectable antipsychotics, like bromperidol decanoate, are used for long-term schizophrenia management.

Purpose of the Study:

• To evaluate depot bromperidol's efficacy and safety against placebo, oral antipsychotics, and other depot preparations in schizophrenia patients.
• To assess clinical, social, and economic outcomes of depot bromperidol treatment.

Main Methods:

• Systematic review of randomized controlled trials identified through comprehensive database searches (Biological Abstracts, Cochrane Library, EMBASE, MEDLINE, PsycLIT) and manufacturer contact.
• Included trials compared depot bromperidol with placebo, oral antipsychotics, or other depot antipsychotics.
• Primary outcomes included mortality, global function, mental state, relapse rates, hospital admissions, adverse effects, and treatment acceptability.

Main Results:

• Four trials (n=117) were analyzed. Bromperidol decanoate showed a trend towards being better than placebo, with fewer dropouts.
• Compared to other depot antipsychotics (fluphenazine decanoate, haloperidol decanoate), bromperidol decanoate was associated with more frequent patient withdrawals.
• No significant differences in adverse effects were observed between bromperidol decanoate and placebo or other depots.

Conclusions:

• Limited data suggest bromperidol decanoate may be superior to placebo but inferior to fluphenazine or haloperidol decanoate for schizophrenia.
• Bromperidol decanoate could be a viable option when other depots are contraindicated.
• High-quality randomized trials are essential to clarify bromperidol decanoate's role in schizophrenia treatment.